The Use of ATP-MgCl2 in the Treatment of Injury and Shock.
Abstract
The purpose of our studies was to determine the safety and hemodynamic response of adenosine triphosphate/magnesium chloride infusion in normal awake human volunteers. In accordance with a protocol approved by the Human Investigation Committee, five healthy adult male volunteers received an intravenous infusion of adenosine triphosphate/magnesium chloride (o.1-0.4mg/kg/min) on four separate occasions. The total dose infused was 3, 6, 10 and 30mg/kg (n=20 studies). Hemodynamic measurements were made at end exhalation in the supine position and included heart rate and systolic, dyastolic and mean blood pressure. Continuous electrocardiographic monitoring of lead II was performed. All hemodynamic changes returned to normal within 2 minutes after the ATP-MgCl2 infusion was discontinued (p=NS). Sodium, potassium, hemoglobin and glucose levels did not change during or after ATP-MgCl2 administration. All subjects experienced transient mild nausea at infusion rates greater than 0.3mg/kg/min. There were no delayed side effects. ATP-MgCl2 is a potent vasodilator. As demonstrated in this study, the increase in cardiac output offset the decrease in total systemic resistance. Thus, blood pressure (MBP) was maintained.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 14, 1984
- Accession Number
- ADA149283
Entities
People
- A. E. Baue
- I. H. Chaudry
Organizations
- Yale University